|
1
|
Speck NA and Gilliland DG: Core-binding
factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2:502–513.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arber DA, Brunning RD, Le Beau MM, Falini
B, Vardiman JW, Porwit A, Thiele J and Bloomfield CD: Acute myeloid
leukaemia with recurrent genetic abnormalities. WHO Classification
of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH,
Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J and
Vardiman JW: 4th edition. IARC Press; Lyon: pp. 110–112. 2008
|
|
3
|
Mrózek K, Heinonen K, Lawrence D, Carroll
AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ,
Schiffer CA and Bloomfield CD: Adult patients with de novo acute
myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to
patients with other translocations involving band 11q23: a Cancer
and Leukemia Group B Study. Blood. 90:4532–4538. 1997.PubMed/NCBI
|
|
4
|
Bloomfield CD, Lawrence D, Byrd JC,
Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT,
Schiffer CA, Arthur DC and Mayer RJ: Frequency of prolonged
remission duration after high-dose cytarabine intensification in
acute myeloid leukemia varies by cytogenetic subtype. Cancer Res.
58:4173–4179. 1998.PubMed/NCBI
|
|
5
|
Grimwade D, Walker H, Oliver F, Wheatley
K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and
Goldstone A: The importance of diagnostic cytogenetics on outcome
in AML: analysis of 1,612 patients entered into the MRC AML 10
trial. The Medical Research Council Adult and Children’s Leukaemia
Working Parties. Blood. 92:2322–2333. 1998.PubMed/NCBI
|
|
6
|
Paschka P, Marcucci G, Ruppert AS, Mrózek
K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW,
Carroll AJ, Kolitz JE, Larson RA and Bloomfield CD; Cancer and
Leukemia Group B. Adverse prognostic significance of KIT mutations
in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer
and Leukemia Group B Study. J Clin Oncol. 24:3904–3911. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park SH, Chi HS, Min SK, Park BG, Jang S
and Park CJ: Prognostic impact of c-KIT mutations in core binding
factor acute myeloid leukemia. Leuk Res. 35:1376–1383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baer MR, Stewart CC, Lawrence D, Arthur
DC, Byrd JC, Davey FR, Schiffer CA and Bloomfield CD: Expression of
the neural cell adhesion molecule CD56 is associated with short
remission duration and survival in acute myeloid leukemia with
t(8;21)(q22;q22). Blood. 90:1643–1648. 1997.PubMed/NCBI
|
|
9
|
Delaunay J, Vey N, Leblanc T, Fenaux P,
Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A,
Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D,
Reiffers J, Castaigne S, Leverger G, Harousseau JL and Dombret H;
French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des
Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de
l’Enfant; Acute Leukemia French Association;
Bordeaux-Grenoble-Marseille-Toulouse cooperative groups. Prognosis
of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110
cases from the French AML Intergroup. Blood. 102:462–469. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schlenk RF, Benner A, Krauter J, Büchner
T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D,
Krahl R, Pasold R, Döhner K, Ganser A, Döhner H and Heil G:
Individual patient data-based meta-analysis of patients aged 16 to
60 years with core binding factor acute myeloid leukemia: a survey
of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol.
22:3741–3750. 2004.PubMed/NCBI
|
|
11
|
Marcucci G, Mrózek K, Ruppert AS, Maharry
K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards
CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA
and Bloomfield CD: Prognostic factors and outcome of core binding
factor acute myeloid leukemia patients with t(8;21) differ from
those of patients with inv(16): a Cancer and Leukemia Group B
study. J Clin Oncol. 23:5705–5717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marková J, Marková J, Trnková Z, Michková
P, Maaloufová J, Starý J, Cetkovský P and Schwarz J: Monitoring of
minimal residual disease in patients with core binding factor acute
myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations
on clinical outcome. Leuk Lymphoma. 50:1448–1460. 2009.PubMed/NCBI
|
|
13
|
Lasota J, Wozniak A, Sarlomo-Rikala M, Rys
J, Kordek R, Nassar A, Sobin LH and Miettinen M: Mutations in exons
9 and 13 of KIT gene are rare events in gastrointestinal stromal
tumors. A study of 200 cases. Am J Pathol. 157:1091–1095. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rubin BP, Singer S, Tsao C, Duensing A,
Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri
GD, Fletcher CD and Fletcher JA: KIT activation is a ubiquitous
feature of gastrointestinal stromal tumors. Cancer Res.
61:8118–8121. 2001.PubMed/NCBI
|
|
15
|
Miselli FC, Casieri P, Negri T, Orsenigo
M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone
A, Pierotti MA, Tamborini E and Pilotti S: c-Kit/PDGFRA gene status
alterations possibly related to primary imatinib resistance in
gastrointestinal stromal tumors. Clin Cancer Res. 13:2369–2377.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kottaridis PD, Gale RE and Linch DC: Flt3
mutations and leukaemia. Br J Haematol. 122:523–538. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thiede C, Koch S, Creutzig E, Steudel C,
Illmer T, Schaich M and Ehninger G: Prevalence and prognostic
impact of NPM1 mutations in 1485 adult patients with acute myeloid
leukemia (AML). Blood. 107:4011–4020. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Verhaak RG, Goudswaard CS, van Putten W,
Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA,
Delwel R, Löwenberg B and Valk PJ: Mutations in nucleophosmin
(NPM1) in acute myeloid leukemia (AML): association with other gene
abnormalities and previously established gene expression signatures
and their favorable prognostic significance. Blood. 106:3747–3754.
2005. View Article : Google Scholar
|
|
19
|
Gulley ML, Shea TC and Fedoriw Y: Genetic
tests to evaluate prognosis and predict therapeutic response in
acute myeloid leukemia (Review). J Mol Diagn. 12:3–16. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sangle NA and Perkins SL: Core-binding
factor acute myeloid leukemia. Arch Pathol Lab Med. 135:1504–1509.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Appelbaum FR, Kopecky KJ, Tallman MS,
Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce
SR and Estey EH: The clinical spectrum of adult acute myeloid
leukaemia associated with corebinding factor translocations. Br J
Haematol. 135:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kern W, Haferlach T, Schoch C, Loffler H,
Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T and
Hiddemann W: Early blast clearance by remission induction therapy
is a major independent prognostic factor for both achievement of
complete remission and long-term outcome in acute myeloid leukemia:
data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood. 101:64–70. 2003. View Article : Google Scholar
|
|
23
|
Germing U, Hildebrandt B, Pfeilstöcker M,
Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C,
Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller
T, Haas R, Gattermann N and Aul C: Refinement of the international
prognostic scoring system (IPSS) by including LDH as an additional
prognostic variable to improve risk assessment in patients with
primary myelodysplastic syndromes (MDS). Leukemia. 19:2223–2231.
2005. View Article : Google Scholar
|
|
24
|
Spoo AC, Lübbert M, Wierda WG and Burger
JA: CXCR4 is a prognostic marker in acute myelogenous leukemia.
Blood. 109:786–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boissel N, Leroy H, Brethon B, Philippe N,
de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine
O, Quesnel B, Baruchel A, Leverger G, Dombret H and Preudhomme C;
Acute Leukemia French Association (ALFA); Leucémies Aiguës
Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence
and prognostic impact of c-Kit, FLT3, and Ras gene mutations in
core binding factor acute myeloid leukemia (CBF-AML). Leukemia.
20:965–970. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dombret H, Preudhomme C and Boissel N:
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose
Ara-C (HDAC) consolidation as effective as you think? Curr Opin
Hematol. 16:92–97. 2009. View Article : Google Scholar : PubMed/NCBI
|
